Sintx Technologies, Inc. (SINT)
NASDAQ: SINT · Real-Time Price · USD
4.240
+0.460 (12.17%)
At close: Aug 28, 2025, 4:00 PM
4.370
+0.130 (3.07%)
After-hours: Aug 28, 2025, 7:56 PM EDT
Sintx Technologies Revenue
Sintx Technologies had revenue of $151.00K in the quarter ending June 30, 2025, a decrease of -82.42%. This brings the company's revenue in the last twelve months to $1.86M, down -40.47% year-over-year. In the year 2024, Sintx Technologies had annual revenue of $2.89M with 9.90% growth.
Revenue (ttm)
$1.86M
Revenue Growth
-40.47%
P/S Ratio
3.74
Revenue / Employee
$93,050
Employees
20
Market Cap
11.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.89M | 260.00K | 9.90% |
| Dec 31, 2023 | 2.63M | 1.07M | 68.29% |
| Dec 31, 2022 | 1.56M | 955.00K | 157.59% |
| Dec 31, 2021 | 606.00K | 12.00K | 2.02% |
| Dec 31, 2020 | 594.00K | -95.00K | -13.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SINT News
- 13 days ago - SINTX Technologies Issues Business Update Following Strategic Realignment, Leadership Expansion, and SiNAPTIC Acquisition - GlobeNewsWire
- 24 days ago - SINTX Technologies Expands Silicon Nitride Platform into Hybrid CFR-PEKK Trauma Plates - GlobeNewsWire
- 2 months ago - SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market - GlobeNewsWire
- 3 months ago - SINTX Technologies Announces Patent Issuance and Formation of Subsidiary to Advance Antimicrobial Applications in the Agribiotech Market - GlobeNewsWire
- 3 months ago - SINTX Technologies Provides Business Update Highlighting Strategic Focus to Medical Device Commercialization - GlobeNewsWire
- 6 months ago - SINTX Technologies Announces $5 Million Private Placement Priced At-the-Market under Nasdaq Rules - GlobeNewsWire
- 6 months ago - SINTX Technologies Sells Technology Assesment and Transfer Subsidiary to Focus on Medical Device Market - GlobeNewsWire
- 6 months ago - SINTX Receives Issuance of U.S. Patent for Silicon Nitride-Functionalized Zirconia-Toughened Alumina Ceramic Biomaterial - GlobeNewsWire